Hormone Therapy for Prostate Cancer

Introduction

If you or someone close to you has been diagnosed with prostate cancer, hormone therapy is likely a term you have heard from your doctor. It is one of the oldest and most widely used treatments for this disease, and it remains a central part of care for many men — from those with high-risk localised cancer to those with cancer that has spread.

Hormone therapy does not work the way surgery or radiation does. It does not cut out or destroy the prostate directly. Instead, it changes the hormonal environment that prostate cancer cells depend on. Because most prostate cancers grow in response to male hormones, lowering or blocking these hormones can slow the cancer down, shrink it, and in many situations extend life by years.

This article explains what hormone therapy is, the different drug types and how they work, when oncologists use it, what side effects to expect, how response is monitored, and how it fits with other prostate cancer treatments. It is written for men who already have a diagnosis and are planning, starting, or continuing this treatment, and for the family members supporting them.

What Is Hormone Therapy for Prostate Cancer?

Hormone therapy for prostate cancer is also called androgen deprivation therapy, or ADT. Androgens are male hormones — mainly testosterone, produced largely by the testicles, and a smaller amount of related hormones made by the adrenal glands above the kidneys. Prostate cancer cells usually carry receptors that bind testosterone, and this binding tells the cells to grow and multiply.

Hormone therapy works in one of two broad ways:

• Reducing how much testosterone the body makes — so that there is less hormone circulating to reach cancer cells.
• Blocking testosterone’s action — so that even if some hormone is present, it cannot signal the cancer cell to grow.

Hormone therapy is not a cure for most advanced prostate cancers on its own. What it does is convert prostate cancer into a slower, more controllable disease for an often long period of time. For men with high-risk localised cancer, hormone therapy combined with radiation has been shown in major trials to improve cure rates compared to radiation alone. For men with cancer that has spread, hormone therapy is usually the backbone of treatment, often combined with newer drugs.

How Hormone Therapy Works

Understanding the hormonal pathway helps make sense of the different drug types your oncologist may discuss.

The brain controls testosterone production through a chain of signals:

1. The hypothalamus in the brain releases a hormone called LHRH (also called GnRH).
2. LHRH tells the pituitary gland to release LH (luteinising hormone).
3. LH travels through the blood to the testicles, which then make testosterone.
4. Testosterone reaches prostate cancer cells, binds to the androgen receptor, and triggers growth.

Hormone therapy can interrupt this pathway at several points: at the pituitary (to stop the testicles from being told to make testosterone), at the testicles themselves (by removing them surgically), at the adrenal glands (to reduce the small additional amount of androgens made there), or at the androgen receptor inside the cancer cell (to block testosterone from binding). Different drug classes act at different points, and they can be combined.

Who Receives Hormone Therapy?

Hormone therapy is used across many stages of prostate cancer. The decision about whether, when, and for how long to use it is made by your oncologist or urologist based on the cancer stage, grade (Gleason score or ISUP grade), PSA level, imaging findings, and your overall health.

Common situations in which hormone therapy is used include:

• High-risk or locally advanced prostate cancer treated with radiation. Major guidelines from organisations such as the NCCN, AUA, and EAU recommend combining radiation therapy with hormone therapy in these cases, typically for a period of months to a few years. The combination has been shown to improve survival compared with radiation alone.
• Recurrent prostate cancer after surgery or radiation — when the PSA starts rising again, sometimes called biochemical recurrence. Hormone therapy may be started alone or after further imaging.
• Metastatic hormone-sensitive prostate cancer — when the cancer has spread to bones, lymph nodes, or other organs, but has not yet been treated with hormone therapy. Modern practice almost always combines ADT with another agent (such as an androgen-receptor pathway inhibitor or chemotherapy) in this setting.
• Castration-resistant prostate cancer — cancer that continues to progress despite testosterone being suppressed. ADT is continued, and additional drugs are added.
• Symptom control in advanced disease, for example reducing bone pain from prostate cancer that has spread to the skeleton.

Hormone therapy is generally not used for low-risk localised prostate cancer that is being managed with active surveillance, surgery alone, or radiation alone.

Types of Hormone Therapy

There are several distinct classes of hormone therapy. Most men will receive one or a combination, and the regimen may change over time as the cancer responds or progresses.

LHRH (GnRH) Agonists

These are the most commonly prescribed hormone therapy drugs. Examples include leuprolide, goserelin, and triptorelin. They are given as injections under the skin or into the muscle, with formulations that last one, three, four, six, or twelve months.

LHRH agonists work by overstimulating the pituitary gland. After an initial brief surge of testosterone, the pituitary stops responding, and testosterone levels drop to very low (“castrate”) levels within a few weeks.

Because of the initial testosterone surge — sometimes called a flare — oncologists usually prescribe a short course of an anti-androgen tablet for a few weeks at the start, particularly in men with significant disease, to prevent flare-related symptoms.

LHRH (GnRH) Antagonists

Examples include degarelix (injection) and relugolix (oral tablet). These drugs block the pituitary directly, so testosterone falls quickly without an initial surge. This avoids the flare and may be preferred when fast testosterone suppression is needed, for example in men with severe bone pain or spinal cord compression risk. Relugolix is also notable because it is taken by mouth rather than as an injection.

Anti-Androgens (First-Generation)

Examples include bicalutamide, flutamide, and nilutamide. These oral tablets block the androgen receptor on the cancer cell, so testosterone cannot bind. They are usually used alongside an LHRH agonist, particularly at the start of treatment to prevent the flare effect, or as part of combined androgen blockade.

Androgen-Receptor Pathway Inhibitors (Second-Generation)

These are newer oral drugs that act on the androgen receptor more powerfully than the first-generation anti-androgens. Examples include enzalutamide, apalutamide, and darolutamide. They are now used at multiple stages of disease — with ADT in metastatic hormone-sensitive disease, in non-metastatic castration-resistant disease, and in metastatic castration-resistant disease. Large clinical trials have shown that adding one of these drugs to standard ADT extends life in many of these settings.

CYP17 Inhibitors

Abiraterone is the main drug in this class. It blocks an enzyme called CYP17, which is involved in making androgens in the testicles, adrenal glands, and prostate cancer cells themselves. Abiraterone is taken as oral tablets together with a low-dose steroid (usually prednisone or prednisolone) to prevent side effects from interfering with adrenal hormone balance. Like the receptor inhibitors, abiraterone is used in both hormone-sensitive and castration-resistant metastatic disease.

Surgical Castration (Bilateral Orchiectomy)

Surgical removal of both testicles — called bilateral orchiectomy — permanently lowers testosterone. It is a small operation, usually done as a day procedure, and the testosterone drop is immediate and lasting. It avoids the need for repeated injections.

Although effective and inexpensive to maintain, orchiectomy is less commonly chosen today because most men prefer reversible medical options, and because the psychological impact of permanent surgery can be significant. It remains a valid choice for men who prefer a one-time treatment, or where consistent access to injections may be difficult.

Oestrogens

Oestrogen-based treatment was historically used to suppress testosterone but is now rarely used as first-line because of cardiovascular side effects. It may occasionally be considered in specific situations.

The Treatment Plan and What to Expect

Your team typically arranges:

• A baseline PSA blood test, and sometimes baseline testosterone.
• Imaging appropriate to your stage — this may include MRI of the prostate, CT scans, bone scan, or PSMA PET scan.
• An assessment of heart and metabolic health, since hormone therapy can affect both. This may include blood pressure, blood sugar, cholesterol, and ECG if relevant.
• A bone density (DEXA) scan, especially if long-term ADT is planned, because hormone therapy can weaken bones over time.
• A discussion of fertility and sexual function. Hormone therapy reduces sperm production and erections; if future biological fatherhood is a consideration, sperm banking before starting treatment may be discussed.

How Treatment Is Given

• Injections: LHRH agonists and antagonists are given by injection or small implant under the skin or into a muscle. Schedules range from monthly to once every six or twelve months.
• Oral tablets: Anti-androgens, androgen-receptor inhibitors, abiraterone, and relugolix are taken by mouth, usually once daily.
• Combinations: Many treatment plans use an injection plus a daily tablet, especially in metastatic disease.

Duration

How long you stay on hormone therapy depends on the clinical situation:

• With radiation for high-risk localised disease, typical durations are around 18 months to 3 years, depending on the protocol.
• With radiation for intermediate-risk disease, shorter courses of around 4 to 6 months are common.
• For biochemical recurrence, duration is individualised and may be continuous or intermittent.
• For metastatic disease, hormone therapy is typically lifelong, with treatment intensified or changed as the disease evolves.

Continuous Versus Intermittent Therapy

For some men, particularly those with non-metastatic disease and slowly rising PSA, oncologists may consider intermittent hormone therapy — cycles of treatment followed by planned breaks while monitoring PSA. The aim is to reduce side effects while still controlling the cancer. Intermittent therapy is not appropriate for all situations, particularly aggressive or widely metastatic disease, where continuous treatment is the standard.

Side Effects and How They Are Managed

• Hot flushes — sudden waves of warmth, sweating, and flushing, similar to those described by women in menopause. They are very common but tend to ease over time.
• Reduced sexual desire (libido) and erectile dysfunction. These changes are usual on ADT. Erectile function may partially recover after treatment ends if therapy was time-limited, but recovery is not guaranteed.
• Fatigue and reduced stamina.
• Loss of muscle mass and strength, and increase in body fat, especially around the waist.
• Breast tenderness or breast tissue growth (gynaecomastia), particularly with anti-androgens.
• Mood changes, including low mood, irritability, or tearfulness.
• Cognitive changes — some men describe trouble with memory or concentration.

Longer-Term and Less Common Effects

• Bone thinning (osteoporosis) and increased fracture risk with prolonged ADT.
• Cardiovascular effects — higher risk of heart disease and stroke. Men with pre-existing heart disease are monitored particularly carefully.
• Metabolic changes — rises in blood sugar, cholesterol, and weight that can increase the risk of diabetes.
• Anaemia — slightly lower red blood cell counts.
• Liver enzyme changes with some oral drugs.
• Specific side effects of newer agents — abiraterone can affect blood pressure, potassium, and liver function; enzalutamide and apalutamide can cause fatigue, falls, and rarely seizures; darolutamide tends to have fewer central nervous system effects.

How Side Effects Are Managed

Care teams use a combination of approaches:

• Exercise — regular aerobic activity and especially resistance (strength) training help protect muscle, bone, mood, and metabolism. Many oncology teams now consider exercise an essential part of ADT care.
• Bone health — calcium and vitamin D supplementation, periodic bone density scans, and, when needed, bone-protective medications such as bisphosphonates or denosumab.
• Cardiovascular monitoring — blood pressure, cholesterol, and blood sugar checks. Existing heart conditions are managed alongside.
• Medications for hot flushes when they are severe.
• Psychological and sexual health support, including counselling. Specific treatments for erectile dysfunction may be offered, though their effectiveness during ADT is limited.
• Diet and weight management support to limit weight gain and metabolic changes.

Hormone therapy is monitored mainly through PSA (prostate-specific antigen), a blood test, along with how you feel and, when relevant, imaging.

• PSA usually falls substantially within weeks to a few months of starting hormone therapy. The depth and speed of the PSA drop give clues about how the cancer is responding.
• Testosterone level may also be checked to confirm that suppression has reached castrate levels.
• Imaging — bone scans, CT, or PSMA PET scans may be repeated at intervals or if symptoms or PSA suggest progression.
• Symptom review — bone pain, urinary symptoms, fatigue, and quality of life are tracked at each visit.

Over time, in some men, prostate cancer learns to grow despite very low testosterone. This is called castration-resistant prostate cancer. It is usually signalled by a rising PSA, new symptoms, or new findings on imaging. At this point, the treatment plan is changed — not by stopping ADT, but by adding or switching to other agents such as an androgen-receptor pathway inhibitor, abiraterone, chemotherapy, radioligand therapy, or, in selected men, targeted therapies based on genetic testing of the tumour.

Combining Hormone Therapy with Other Treatments

Hormone therapy is rarely used in isolation in modern prostate cancer care. The combinations depend on disease stage and goals.

With Radiation Therapy

For intermediate- and high-risk localised cancer, oncologists commonly add hormone therapy to external beam radiation. Trials have shown that this combination improves cure rates compared with radiation alone. The hormone therapy is often started before radiation, continued during it, and extended for a defined period afterwards.

With Surgery

Hormone therapy is generally not given before prostate surgery (radical prostatectomy) outside of clinical trials. It may be considered after surgery in selected high-risk situations, often together with radiation.

With Chemotherapy

For men with metastatic hormone-sensitive prostate cancer, especially when the cancer burden is high, adding chemotherapy (usually docetaxel) to ADT has been shown to extend survival in major trials. Some men may receive a triple combination of ADT, an androgen-receptor pathway inhibitor or abiraterone, and chemotherapy.

With Newer Targeted and Radioligand Therapies

In castration-resistant disease, additional treatments are layered on top of continued ADT — including PARP inhibitors for men with certain genetic mutations (such as BRCA1/2), and radioligand therapy such as Lutetium-177 PSMA for selected men with PSMA-positive metastatic disease. These decisions involve genetic testing of the tumour and specialised imaging.

Living During Hormone Therapy

Hormone therapy is often a long part of life rather than a short event, so day-to-day adjustments matter.

Physical Activity

Regular exercise is one of the most important things a man on hormone therapy can do for himself. Aerobic exercise (walking, cycling, swimming) supports heart health and mood. Resistance training (using weights or resistance bands) helps protect muscle and bone. Many cancer centres now offer or recommend structured exercise programmes alongside ADT.

Nutrition

A balanced diet rich in vegetables, fruit, whole grains, lean protein, and adequate calcium and vitamin D supports bone, heart, and metabolic health. Limiting processed foods, excess sugar, and alcohol is generally advised. A dietitian can help individualise this, especially if blood sugar or cholesterol changes appear.

Sexual Health and Relationships

Changes in sexual desire and function are among the most personal effects of hormone therapy. They can affect mood and relationships. Talking openly with your partner, and with a counsellor or sexual health specialist when needed, helps couples adapt. Some men explore options to maintain intimacy that do not depend on erections; medical treatments for erectile dysfunction have a limited but sometimes useful role during ADT.

Emotional Health

Low mood, anxiety, and a sense of loss are common and understandable. Support groups, professional counselling, and mental health treatment when needed can make a real difference. Family members and partners often benefit from support too.

Work and Daily Life

Most men continue to work and travel during hormone therapy. Fatigue may require pacing during the day, particularly in the first few months, and exercise often helps energy levels in the long run.

Stopping or Changing Hormone Therapy

If hormone therapy is being given for a defined period — for example, alongside radiation — it is stopped at the end of that period. Testosterone levels often recover over months to a few years afterwards, though recovery is slower in older men and may be incomplete. Sexual function, energy, and body composition may partially return as testosterone rises.

If hormone therapy is being given for metastatic or recurrent disease, it is generally continued indefinitely, even when other treatments are added. Stopping ADT in this setting is not usually recommended because it can allow the cancer to grow more quickly.

Any change to the regimen — a switch to a different drug, the addition of a new agent, or a planned break in intermittent therapy — is made by your oncology team based on response and side effects.

Outlook

The outlook with hormone therapy varies widely depending on cancer stage and biology. Some general patterns are helpful to understand:

• For men with high-risk localised cancer treated with radiation plus hormone therapy, long-term cancer control and cure are achievable in a substantial proportion.
• For men with metastatic hormone-sensitive cancer, modern combination treatment has meaningfully extended survival compared with ADT alone, often by years.
• For men whose cancer becomes castration-resistant, additional treatment options continue to grow, and many men live for further years with active disease management.

Your own outlook is shaped by many factors — cancer stage and grade, PSA dynamics, genetic features of the tumour, your overall health, and how the cancer responds to treatment. Specific estimates are best discussed with your oncologist, who knows your full picture.

Frequently Asked Questions

Is hormone therapy a cure for prostate cancer?
On its own, hormone therapy is usually not a cure, especially for advanced disease. When combined with radiation for high-risk localised cancer, it contributes to cure in many men. For metastatic disease, it is a powerful long-term control treatment rather than a cure.

Is hormone therapy the same as chemotherapy?
No. Chemotherapy uses drugs that directly attack rapidly dividing cells throughout the body. Hormone therapy changes the hormonal signals that prostate cancer cells depend on to grow. The two treatments have very different side-effect profiles and are sometimes combined.

Will I lose my fertility?
Hormone therapy significantly reduces sperm production. For men who may want to father a biological child in future, sperm banking before starting treatment is something to discuss with your doctor.

Will my sex life change?
Most men experience reduced sexual desire and difficulty with erections during hormone therapy. The degree varies. After time-limited therapy, function may partly return; with long-term therapy, changes typically persist. Sexual health specialists can offer practical strategies and treatments.

Do I need to stop working?
Most men continue working. Fatigue is the most common reason to adjust schedules, especially early in treatment. Office and most other jobs are generally manageable.

How is my response to treatment measured?
Mainly through the PSA blood test, sometimes alongside testosterone testing, imaging, and symptom review. A falling PSA usually signals a good response.

What happens if my PSA starts rising again?
A rising PSA on hormone therapy may indicate that the cancer is becoming castration-resistant. Your team will reassess with imaging and may add or switch to another treatment. ADT itself is usually continued.

Is surgical removal of the testicles still used?
Yes, but less often than in the past. It is an effective and permanent way to lower testosterone and is offered as one option, particularly for men who prefer a one-time procedure to ongoing injections.

Are oral tablets as effective as injections?
For lowering testosterone, the oral LHRH antagonist relugolix achieves similar suppression to injections in clinical trials. Other tablet hormone therapies, such as anti-androgens, androgen-receptor pathway inhibitors, and abiraterone, are used in addition to or instead of injections at different disease stages, depending on the situation.

Can lifestyle changes really make a difference?
Yes. Exercise — particularly resistance training — along with a balanced diet, adequate calcium and vitamin D, not smoking, and limiting alcohol, has been shown to reduce many of the metabolic, bone, and emotional effects of hormone therapy.

Conclusion

Hormone therapy has been a cornerstone of prostate cancer treatment for decades, and it remains so today — now alongside a growing range of newer drugs that work together with it to extend life and improve disease control. For men with high-risk localised cancer, it strengthens the chance of cure when combined with radiation. For men with advanced disease, it forms the foundation on which other treatments are layered.

The experience of hormone therapy is shaped both by the disease and by how the side effects are anticipated and managed. With attention to exercise, bone and heart health, emotional wellbeing, and open communication with the care team, many men live full and active lives during treatment. The plan is personal and evolves over time, guided by PSA, imaging, symptoms, and the broader picture of your health — in close partnership with your oncologist.